Omeros Corporation clinical trials
The registry lists 25 studies whose lead sponsor is Omeros Corporation. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 2, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 25studies on the registry
- 1open to participants now
- 1reach primary completion within a year
Get an email when these change. Save the Omeros Corporation studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
What it is testing
The drugs Omeros Corporation’s studies test, most open studies first — 4 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
Coming up
1 of Omeros Corporation’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
What changed recently
From the registry's own updates since Oct 14, 2026.
Stopped1
- Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNTerminatedNov 2, 2026NCT06209736
All 25 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 09
- 10
- 11
- 12
- 13
- 414
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 3 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Omeros Corporation.
- Omeros Corporation25 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 25 of 25.
- Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMARecruitingNCT05855083Phase 2
- Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNTerminatedNCT06209736Phase 2
- Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingNCT06298955Phase 2
- Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT05889299Phase 1
- Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721TerminatedNCT02682407Phase 2
- Single Patient Expanded Access Treatment Plan For The Investigational Product NarsoplimabApproved for marketingNCT04247906
- Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromeTerminatedNCT03205995Phase 3
- Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyTerminatedNCT03608033Phase 3
- Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to RavulizumabCompletedNCT05972967Phase 2
- Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesCompletedNCT02222545Phase 2
- A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens ReplacementCompletedNCT02132312Phase 3
- Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic MeniscectomyCompletedNCT01406561Phase 3
- Safety and Efficacy of OMS643762 in Subjects With Huntington's DiseaseTerminatedNCT02074410Phase 2
- Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia SubjectsCompletedNCT01952132Phase 2
- Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement SurgeryTerminatedNCT02093689Phase 3
- Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With PhacoemulsificationCompletedNCT01579565Phase 3
- Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)CompletedNCT01193127Phase 2
- Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With PhacoemulsificationCompletedNCT01454063Phase 3
- Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.CompletedNCT00721695Phase 1/2
- Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) ReconstructionCompletedNCT00226772Phase 3
- Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) ReconstructionCompletedNCT00226759Phase 3
- Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract StonesCompletedNCT00857090Phase 1/2
- Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) ReconstructionCompletedNCT00245271Phase 3
- Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing MeniscectomyCompletedNCT00624845Phase 2/3
- Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located StonesCompletedNCT00599664Phase 1